E-cadherin and [beta]-catenin Loss of Expression Related to Bone Metastasis in Prostate Cancer

• Published in: Applied immunohistochemistry & molecular morphology Vol. 18; no. 2; pp. 179 - 184
• Main Authors: Junior, J P, Srougi, M, Borra, PMA, Dall'Oglio, M F, Ribeiro-Filho, LA, Leite, KRM
• Format: Journal Article
• Language: English
• Published: 01-03-2010
• ISSN: 1541-2016
• DOI: 10.1097/PAI.0b013e3181640bca

Objectives: E-cadherin and b-catenin are adhesion molecules responsible for the maintenance of normal epithelial cell phenotype. A disturbance in epithelial cell adhesion, which leads to a more invasive and metastatic phenotype, is a hallmark of tumor progression. Several immunohistochemical studies have reported a strong correlation between loss of their expression to higher stage and grade in prostate carcinoma, but their influence in metastatic process is not yet known. The aim of this study is to verify the role of adhesion molecules in the progression of prostate cancer (PC), assessing the expression of E-cadherin and b-catenin in bone metastasis. Materials and Methods: Twenty-eight bone metastases of prostate carcinoma were submitted to immunohistochemistry analysis for E-cadherin and b-catenin expression. In 6 patients, we were able to assess the expression of the adhesion molecules in the primary tumors and their respective metastases. The definition of normal expression for both antibodies was strong and diffuse expression in more than 70% of tumor cells. Results: In bone metastases, there was loss of expression of E-cadherin and b-catenin in 86% and 82%, respectively. Among the primary tumors, E-cadherin and b-catenin expression was normal in 83% and 50% cases, respectively. Considering the 6 patients with paired primary and bone metastasis, we found loss of expression for both E-cadherin and b-catenin in most of the cases. Conclusions: Comparing primary PC and its metastasis, we showed persistent loss of E-cadherin and b-catenin expression. This phenomenon may be related to metastatic potential in PC, because we have shown underexpression for E-cadherin and b-catenin in 86% and 82% of bone metastases.